G2295
格列美脲
≥98% (HPLC), insulin secretagogue, solid
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H34N4O5S
化学文摘社编号:
分子量:
490.62
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
格列美脲, ≥98% (HPLC), solid
Quality Level
assay
≥98% (HPLC)
form
solid
color
white
mp
212.2-214.5 °C
solubility
DMSO: >10 mg/mL
originator
Sanofi Aventis
storage temp.
room temp
SMILES string
CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O
InChI
1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-
InChI key
WIGIZIANZCJQQY-RUCARUNLSA-N
Gene Information
human ... ABCC8(6833), KCNJ1(3758), KCNJ11(3767)
General description
格列美脲属于生物制药II类二代磺酰脲类药物。
Application
格列美脲已被用于：
- 作为一种降糖药物用于测试其在人脐静脉细胞（HUVEC）中的抗糖尿病功能
- 在乳腺癌MDA-MB-231细胞中作为磺酰脲类ATP敏感型钾通道（KATP）抑制剂
- 在新生儿胰岛样细胞簇（NICC）的葡萄糖刺激胰岛素分泌（GSIS）测定中检测其对胰岛素分泌的影响
格列美脲目前用于治疗 2 型糖尿病。
Biochem/physiol Actions
心脏 KATP 通道的强力阻断剂。
格列美脲可通过刺激胰腺β细胞分泌胰岛素激素来降低血糖水平。它可与与β细胞相关的一种65-kD蛋白发生相互作用。
格列美脲是一种有效的心肌梗死 KATP 通道阻断剂，被吡那地尔激活，IC50 值为 6.8 nM。
Features and Benefits
该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。
Still not finding the right product?
Explore all of our products under 格列美脲
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| G2295-50MG | 04061833628805 |
| G2295-250MG | 04061832574530 |